Tarsus Pharmaceuticals, Inc. is a high-risk pharmaceutical company based in the United States. Specializing in eye care, Tarsus Pharmaceuticals focuses on developing and commercializing innovative therapeutic candidates to treat ophthalmic conditions. The company's leading candidate, XDEMVY, is a novel investigational eye drop designed to treat Demodex blepharitis, caused by Demodex mites infestation. With an ESG score of 32.0, Tarsus Pharmaceuticals is committed to environmental sustainability and governance in the pharmaceutical industry.